BioXcel Therapeutics | TalkMarkets

Latest Posts

Six Of Seven AI Stock Categories Increased This Week

Article By: Lorimer Wilson

Saturday, March 23, 2024 6:19 PM EDT

All but one of the 7 artificial intelligence stock categories I analyze increased in value this week. But there are indications that the surge in the AI technology sector is slowing.

In this article: BTAI, AIQ, AMAT, CDNS, MU, NVDA, SNPS, TENB, CRWD, LTRN Also: HON, HPQ, EXAI, BIDU, AVGO, INTC, LRCX, ANET, CYBR, DELL

Read

AI-Powered Drug Discovery Stocks Index Up 9% In February; Remains Down 8% YTD

Article By: Lorimer Wilson

Monday, March 4, 2024 12:41 AM EDT

Grand View Research says the global "AI in drug discovery" market should expand at a CAGR of 30% between now, and 2030 which Morgan Stanley believes will lead to 50 novel therapies over the next decade, with annual sales in excess of $50 billion.

In this article: EXAI, SDGR, ABCL, BTAI, RLAY, LTRN, ABSI, RXRX

Read

AI-Powered Drug Discovery Stocks Index Up 18% Last Week, Led By BioXcel Therapeutics

Article By: Lorimer Wilson

Monday, February 19, 2024 12:05 AM EDT

The AI-powered drug discovery market is projected to grow at a 30% CAGR between now and 2030, with annual sales in excess of $50 billion anticipated. An AI drug discovery revolution is underway.

In this article: EXAI, SDGR, ABCL, BTAI, RLAY, LTRN, ABSI, RXRX

Read

AI-Focused Drug Discovery Stocks Index Up 26% In December

Article By: Lorimer Wilson

Friday, December 29, 2023 11:49 AM EDT

With the promise of lower costs and shorter development timelines, AI-enabled drug discovery holds massive potential to increase the accessibility of drugs and to treat presently incurable conditions.

In this article: EXAI, SDGR, ABCL, BTAI, RLAY, LTRN, ABSI, RXRX

Read